Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - Alaunos Therapeutics

Next Previous
X
Search
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Alaunos Therapeutics

Alternative Names: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells; CD19-CD8CD28zCAR-specific-mbIL15-HER1t T-lymphocytes; CD19RCD28; RPM CD19-mbIL15-CAR-T cells

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intrexon Corporation
  • Developer Alaunos Therapeutics; Eden BioCell; National Cancer Institute (USA); National Taiwan University Hospital; Precigen Inc; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported B-cell lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Second-line therapy or greater) in Taiwan (IV, Injection)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Late-stage disease, Second-line therapy or greater) in Taiwan (IV, Injection)
  • 03 Apr 2023 Precigen regains its erxclusive rights from Alaunos Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top